Zhejiang Jolly Pharmaceutical 佐力药业
27 significant filings since 30 May 2026: 19 on share issue, 6 on equity incentive and 1 on dividend, and 1 other kind. The latest, on 15 Sep 2026: 2026年半年度权益分派实施公告.
自 30 May 2026 起有 27 份重大公告：share issue 19 份、equity incentive 6 份、dividend 1 份，另有 1 类。最新一份（15 Sep 2026）：2026年半年度权益分派实施公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,龙永茂 | Buy 买入 | 12 Sep 2026 | 3 | — |
| 开源证券 | 余汝意,巢舒然 | Buy 买入 | 1 Sep 2026 | 2 | — |
| 东吴证券 | 朱国广,向潇 | Buy 买入 | 30 Apr 2026 | 3 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 8 reports. 每行为该券商近十二个月的最新研报；8 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。